Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open study in phase II to evaluate efficacy of initial R-CHOP [rituximab, cyclophosphamide, adriamycin, vincristine and prednisone] combination in folicular lymphoma no treated previously. Consolidation with one dose of 90Y ibritumomab tiuxetan (Zevalin) versus maintenance treatment with rituximab (MabThera)

Trial Profile

Open study in phase II to evaluate efficacy of initial R-CHOP [rituximab, cyclophosphamide, adriamycin, vincristine and prednisone] combination in folicular lymphoma no treated previously. Consolidation with one dose of 90Y ibritumomab tiuxetan (Zevalin) versus maintenance treatment with rituximab (MabThera)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibritumomab tiuxetan (Primary) ; Rituximab (Primary)
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Apr 2020 Status changed from suspended to completed.
    • 27 Oct 2014 Status changed from recruiting to suspended due to no inclusion, as reported by ClinicalTrials.gov
    • 10 Dec 2013 Interim results presented at the 56th Annual Meeting and Exposition of the American Society of Hematology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top